Interplay between COVID-19 and Secukinumab treatment in Spondylarthritis patients during the omicron surge: a retrospective cohort study-Reference-Cited by-全球学者库

Interplay between COVID-19 and Secukinumab treatment in Spondylarthritis patients during the omicron surge: a retrospective cohort study

Published:2023-12-13 Issue:1 Volume:57 Page:
ISSN:0891-6934
Container-title:Autoimmunity
language:en
Short-container-title:Autoimmunity

Author:

Wu Tong¹²³,Li Yanhong¹²³,Huang Deying¹²³,Wu Yinlan¹²³,Liang Xiuping¹²³,Cheng Lu¹²³,Liao Zehui⁴,Xu Fang⁴,Chen Ye¹²³,Zhao Jing¹²³,Xia Zijing¹²³,Tan Chunyu¹²³,Liu Yi¹²³,Herrmann Martin⁵⁶

Affiliation:

1. Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China

2. Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China

3. Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, China

4. Meishan People’s Hospital, Meishan, China

5. Department of Medicine 3, Universitäts-klinikum Erlangen, Erlangen, Germany

6. Deutsches Zentrum Immuntherapie DZI, Universitätsklinikum Erlangen, Erlangen, Germany

Funder

Sichuan Province Science and Technology Support Program

West China Hospital, Sichuan University

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/08916934.2023.2281242

Reference30 articles.

1. WHO. Pneumonia of unknown cause-China Disease Outbreak News. https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-causechina/en/

2. WHO. Virtual press conference on COVI-19- 11. 2020.

3. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis

4. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

5. COVID-19: consider cytokine storm syndromes and immunosuppression